ABN Newswire is a business newswire and press release distribution service for listed companies on stock exchanges globally. ABN Newswire distributes company announcements to the professional platforms, finance portals and syndicates important corporate news to a wide variety of news aggregators and financial news systems.
Carl Zeiss Meditec AG (OJ:AFX) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
(Dublin/Calif. / Jena, 6 November 2008) Effective 5 November 2008, Carl Zeiss Meditec acquires all assets related to the manufacturing of two glaucoma diagnostic products from its long standing OEM supplier Welch Allyn, a leading manufacturer of frontline medical products and solutions. This is set out in an agreement between the two leading medical technology providers as signed yesterday. The assets acquired consist mainly of IP and manufacturing rights and design know-how. Both parties agreed on not disclosing any economic details of the agreement.
About Carl Zeiss Meditec
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's leading medical technology companies. This market position is based on over 160 years of experience in optical innovation.
The company has two primary areas of activity: In the field of ophthalmology Carl Zeiss Meditec offers integrated solutions for treating the four main eye diseases: vision defects (refraction), cataracts, glaucoma and retinal disorders. In the field of neuro and ENT surgery, Carl Zeiss Meditec is the world's leading provider of surgical microscopes and microsurgical visualisation solutions for a very broad range of applications, such as tumor and vascular surgery in the head region and/or spinal surgery.
Carl Zeiss Meditec's medical technology portfolio is rounded off by visualisation systems for doctors in private practice and promising future technologies such as intraoperative radiation therapy, which allows the targeted treatment of breast cancer and brain cancer directly during surgery.
Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany (Carl Zeiss Surgical GmbH, Carl Zeiss Meditec Vertriebsgesellschaft mbH, Acri.Tec GmbH and Carl Zeiss Medical Software GmbH), the USA (Carl Zeiss Meditec, Inc., Dublin California), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl Zeiss Meditec Iberia S.A., Madrid) and France (Carl Zeiss Meditec S.A.S, La Rochelle, and Carl Zeiss Meditec France SAS, Le Pecq).
About Welch Allyn Founded in 1915 and headquartered in Skaneateles Falls, New York (USA), Welch Allyn is a leading global manufacturer of medical diagnostic equipment and a complete range of digital and connected solutions. With over 2,300 employees working in 17 different countries, Welch Allyn specializes in helping doctors, nurses and other frontline practitioners across the globe provide the best patient care by developing innovative products, breakthrough technologies and cutting-edge solutions that help them see more patients, detect more conditions, and improve more lives. More information about Welch Allyn and its complete line of connected products and solutions may be found at www.welchallyn.com.
Media Contact Welch Allyn: Jamie Arnold, APR / Public Relations Manager P: 315.685.4599 @: arnoldj@welchallyn.com www.welchallyn.com
--- End of Message ---
Carl Zeiss Meditec AG Goeschwitzer Strasse 51-52 Jena Germany
WKN: 531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, TecDAX; Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in Frankfurter Wertpapierbörse;